Julie Rubinstein, the President and COO of Adaptive Biotechnologies Corporation, recently filed a Form 4 with the SEC, detailing her transactions involving the company's common stock. This filing, dated October 26, 2026, highlights significant stock activity that may impact the perception of the company's management and its strategic direction.
Adaptive Biotechnologies, based in Seattle, Washington, is a leader in the life sciences sector, specifically focusing on biological products. The company has made a name for itself in developing innovative therapies and diagnostics, which are crucial in today's healthcare landscape. The recent filing is part of a series of disclosures made by Rubinstein, indicating active management engagement in the company's equity.
The filing reveals that on October 22, 2026, Rubinstein acquired 11,881 shares of common stock at a price of $12.14 per share. Additionally, she reported the sale of shares on the same date, including 10,181 shares at a price of $24.38 and 1,700 shares at $25.29. This pattern of buying and selling shares suggests a strategic approach to managing her holdings within the company.
On October 23, 2026, Rubinstein continued her activity by acquiring another 11,881 shares at the same price of $12.14 and selling 4,500 shares at $24.50 and 7,381 shares at $25.28. The transactions on October 26 included the acquisition of 11,881 shares at $12.14 and the sale of 8,503 shares at $25.94, followed by another sale of 3,378 shares at $26.30.
Following these transactions, Rubinstein's total ownership in Adaptive Biotechnologies stands at 377,802 shares. The transactions were executed under a Rule 10b5-1 trading plan, which allows executives to set up a predetermined schedule for buying and selling stock, thereby reducing the risk of insider trading allegations.
The implications of these transactions are significant for both the company and its investors. As a key executive, Rubinstein's actions can influence investor confidence and market perceptions. The life sciences industry is highly competitive, and the strategic management of stock holdings can reflect broader company strategies and outlooks.
Looking ahead, it remains to be seen how these transactions will affect Adaptive Biotechnologies' stock performance and investor relations. The filing does not specify any upcoming events or additional filings related to these transactions.